Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laurie Aten

Family Medicine Denton, TX Medical Doctor

NPI 1447364468 CMS profile 246627

2817 S Mayhill Rd, Suite 230, Denton, TX 76208

Open in the dashboard

General payments

$1,697

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laurie Aten of Denton, TX is reported in the CMS Open Payments database as having received $1,697 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $86 4
2024 General $238 11
2023 General $548 19
2022 General $158 11
2021 General $191 16
2020 General $284 3
2019 General $191 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laurie Aten
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Laurie Aten were reported at $86. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Laurie Aten Family Medicine median Middle half National median
2019 $191 $150 $41–$543 $163
2020 $284 $120 $32–$415 $114
2021 $191 $137 $35–$551 $132
2022 $158 $137 $37–$512 $149
2023 $548 $149 $42–$545 $160
2024 $238 $156 $44–$560 $164
2025 $86 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $742 56 payments
  2. Musculoskeletal Transplant Foundation Inc. $280 2 payments
  3. BSN Medical Inc $207 1 payment
  4. Organogenesis Inc. $155 8 payments
  5. KCI USA, Inc $53 3 payments
  6. NormaTec Industries, LP $39 1 payment
  7. Urgo Medical North America, LLC $37 2 payments
  8. Edwards Lifesciences Corporation $32 1 payment
  9. Milliken Healthcare Products, LLC $27 1 payment
  10. Solventum Corporation $26 1 payment
  11. Other $98 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,697 83 payments
Products named General payments · program years 2019–2025
  1. GRAFIX PL Other Advanced Wound Management $278 17 payments
  2. CUTIMED SORBACT $207 1 payment
  3. OASIS $176 8 payments
  4. COLLAGENASE SANTYL $161 10 payments
  5. Puraply $155 8 payments
  6. Santyl $87 10 payments
  7. ACTIV.A.C. $64 3 payments
  8. REGRANEX $56 7 payments
  9. GRAFIX PL Other Advanced Wound Management $55 2 payments
  10. Grafix PL PRIME $42 5 payments
  11. Other $717 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

337

Median for Preventive Medicine: 100

Drug cost

$12,194

Median for Preventive Medicine: $5,055

Branded share of claims

31.2%

Median for Preventive Medicine: 27.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 14 $7,445
Mupirocin Generic 128 $995
Doxycycline Monohydrate Generic 56 $984
Metronidazole Generic 14 $832
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 43 $619
Cefuroxime Cefuroxime Axetil Brand 19 $513
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 16 $281
Mometasone Furoate Generic 19 $212
Ciprofloxacin Hcl Generic 15 $205
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $109

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 584 Part D prescribers listed as Preventive Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$55,661

Medicare's payments for the services billed

Medicare patients

80

Average age 76

Services billed

1,153

40 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Chronic kidney disease 59%
Diabetes 58%
Ischemic heart disease 51%
Atrial fibrillation 46%
Heart failure 35%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record